Literature DB >> 19403938

Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

C Serrate, Y Loriot, T De La Motte Rouge, M Gross-Goupil, C Massard, B Escudier, A Bossi, K Fizazi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403938     DOI: 10.1093/annonc/mdp112

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

Review 1.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

2.  Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor.

Authors:  Hao Wang; Jiang Li; Yang Gao; Ying Xu; Ying Pan; Ichiro Tsuji; Zi-Jie Sun; Xiao-Meng Li
Journal:  Asian J Androl       Date:  2010-05-03       Impact factor: 3.285

3.  [Change of the LHRH analogue in progressive castration-refractory prostate cancer].

Authors:  A Heidenreich; D Porres; R Epplen; T van Erps; D Pfister
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

Review 4.  Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum.

Authors:  Leonardo Oliveira Reis
Journal:  Med Oncol       Date:  2011-05-28       Impact factor: 3.064

5.  Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.

Authors:  Julia Clemons; L Michael Glodé; Dexiang Gao; Thomas W Flaig
Journal:  Urol Oncol       Date:  2011-07-27       Impact factor: 3.498

Review 6.  Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.

Authors:  George Orphanos; Alexandros Ardavanis
Journal:  Clin Exp Metastasis       Date:  2009-11-11       Impact factor: 5.150

7.  Redefining hormone sensitive disease in advanced prostate cancer.

Authors:  Xiaoyu Hou; Thomas W Flaig
Journal:  Adv Urol       Date:  2012-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.